86 results about "Angiotensin receptor" patented technology

The invention is directed to a method for accelerating the cell cycle by delivering to a cell an effective amount of electromagnetic energy. The invention also provides a method for activating a cell cycle regulator by delivering to a cell an effective amount of electromagnetic energy. Also provided by the invention is a method for activating a signal transduction protein; a method for activating a transcription factor; a method for activating a DNA synthesis protein; and a method for activating a Receptor. A method for inhibiting an angiotensin receptor as well as a method for reducing inflammation also are provided by the present invention. The invention also is directed to a method for replacing damaged neuronal tissue as well as a method for stimulating growth of administered cells.

The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.

A pharmaceutical composition comprising enantiomerically pure (S)-amlodipine, an ARB and optional other active agents, and methods of treating, preventing and managing cardiovascular diseases and disorders, and symptoms thereof, using the composition, are disclosed.

The invention relates to the composition of a novel formulation of eprosartan with enhanced bioavailability. The formulation comprises of eprosartan or a salt, solvate, or hydrate thereof, a solubilizer, and an emulsifier. A process for manufacturing, and methods of using the formulation to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure are also provided.

The present application is directed to the identification of mutations and / or polymorphisms in the Dual Endothelin-1 / Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear.

Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

The invention relates to an angiotensin receptor inhibitor and a solid preparation of amlodipine and a novel method for preparing the same. The method comprises the following steps that: 1, valsartan and amlodipine are screened respectively until the grain size of the valsartan and amlodipine is qualified; 2, the valsartan and amlodipine are added with proper amount of excipient respectively and the mixture is evenly mixed; and 3, the evenly mixed powder are added with proper amount of bonding agent or wetting agent respectively to obtain grain in proper grain size, and the grain is dried.

Methods and compositions are disclosed to treat neuropsychiatric disorders post-traumatic stress disorder (PTSD). In particular, described herein are angiotensin receptor blockers (ARBs), and in particular the combination of one or more ARB (such as telmisartan) and an agent that enhances the delivery of the ARB across the blood-brain barrier (such as minocycline). PTSD may be treated using a combination of telmisartan and minocycline at levels of each that are, by themselves, infective to treat PTSD. Also described herein are methods for treating PTSD by first identifying patents for whom the use of an ARB treatment would be effective, by determining that patient has a dysfunction in their angiotensin converting enzyme and / or other genes in the autonomic arousal axis.

The invention discloses an angiotensin II receptor 1 type polypeptide-vector vaccine and an application thereof, belonging to the field of biotechnology drugs and biologic therapeutics. An angiotensin II receptor 1 type immunogenic peptide containing a first connection locus, a derivant thereof and one or more of carriers are preferably coupled and connected with recombined Qbeta-2aa bacteriophage viruslike particle protein to form an ordered and repeated polypeptide-carrier vaccine. The invention also discloses an application of the vaccine on the aspect of treating primary hypertension. Thevaccine can generate one section of efficient specific immunogenic peptide resisting human angiotensin II receptor 1 type and the antibody of the derivant thereof. RAS (Renin-Angiotensin System) can be effectively prevented from activating, the blood pressure of spontaneously hypertensive rats can be obviously lowered, and the vector vaccine has good function on protecting target organs.

The present invention relates to pharmaceutical compositions for reducing essential hypertension and systemic inflammation. While many drugs have been found to treat hypertension, the currently available drugs often do not maintain reduced blood pressure at the preferred norm of 115 / 75 mm Hg or less throughout a 24 hour period. The current invention provides compositions comprising at least one hypertensive drug combined with the natural product Coenzyme Q10 (ubiquinone or CoQ10), which synergizes with the antihypertensive drugs to maintain low blood pressure throughout the day and night while generating other positive effects on the risks of cardiovascular disease, renal failure, and stroke. CoQ10 also counteracts some of the side effects of some hypertensive drugs such as tiredness, weakness, and / or liver toxicity. The invention further describes therapeutically effective methods for reducing systemic inflammation in hypertensive mammals comprising treatment with an antihypertensive composition that includes at least one angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and CoQ10 (ubiquinone). The invention metrics for reducing systemic inflammation comprise the reduction of serum levels of high sensitivity C-reactive protein (CRP), Interleukin 6 (IL-6), and / or tumor necrosis factor-alpha (TNF-alpha). These antihypertensive-CoQ10 combinations will synergistically reduce both hypertension and systemic inflammation.

The present invention relates to a method of increasing the bioavailability of angiotensin II receptor blockers (ARBs) by preparing a combination of the ARB and at least one solubility enhancer. The present invention particularly relates to solubility enhancers that not only function as solubility enhancers but also improve the dissolution rate in particular in acidic or weakly acidic media where the dissolution of ARBs is minimal. In the composition, the ARB can be present as a physical mixture, solid dispersion, solid solution or complex with the solubility enhancer. Combinations of ARBs and solubility enhancers can be incorporated into immediate or controlled release or other suitable modified release formulations. Immediate release formulations comprising ARB compositions have an in vitro release of at least 40% in acidic media (pH<3). Thus, the bioavailability of the ARB can be increased by at least 20%, as measured by Cmax, AUC0-t and AUC0-∞.

The present invention provides, inter alia, methods for treating or ameliorating the effects of a glioma. Methods of this invention include administering to a subject in need thereof an effective amount of a first active agent, such as e.g., an angiotensin receptor blocker, an antifungal agent, a bisphosphonate, an oxytocin inhibitor, an interleukin-1 (IL-1) inhibitor, a cyclooxygenase inhibitor, an α2δ voltage-dependent calcium channel (VDCC) inhibitor, a dihydroorotate dehydrogenase inhibitor, a calcium channel blocker, a renal sodium-chloride symporter inhibitor, an a2 adrenergic agonist, a phenothiazine antipsychotic, a calcineurin inhibitor, a 5-HT agonist, an angiotensin-converting enzyme (ACE) inhibitor, a direct rennin inhibitor, or combinations thereof, and a second active agent, which is a chemotherapeutic agent. Compositions for treating or ameliorating the effects of a glioma are also provided.

The invention discloses an application of taking oligopeptide and derivatives thereof as a template molecule, and an imprinting technology based preparation method of an angiotensin synthetic receptor. The template molecule comprises any section of a peptide bond at a nitrogen end or a carbon end of an angiotensin II, and derivatives thereof, or any section of the peptide bond at the nitrogen end or the carbon end of an angiotensin I and the derivatives thereof. The application takes the template molecule as an imprint to prepare the angiotensin synthetic receptor; the angiotensin acceptor is prepared in a way that the template molecule, a function monomer, a cross-linking agent, a surface-active agent and the like are mixed according to a certain rate, and then an initiator is added. The acceptor is good in biocompatibility, can high selectively capture and neutralize the angiotensin II and the angiotensin I, and cuts off functions of the angiotensin II and the angiotensin acceptor (AT1) as well as functions of the angiotensin I and angiotensin converzyme (ACE), so as to control the blood pressure. The acceptor can be applied to separation, concentration and measuring of the angiotensin I or II.

Parmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.

The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis cancer metastasis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and / or treat conditions associated with c-Met dysregulation, including altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.

The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and / or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.

The invention relates to a N-aryl substituted-1H pyrrole derivative or its salt having cardiovascular activity represented by formula (I), which has activity angiotensin II (AII) acceptor antagonism and can be applied in treating cardiovascular diseases e.g. hypertension, hyperemia heart failure, myocardium pachismus, vasospasm and other diseases or symptoms treated through blockading AII acceptor.

Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an vaccine. The invention also provides related methods of inhibiting tumor growth and metastasis by administering to an individual with cancer an angiotensin II receptor blocker or a compound of Formula (I) in conjunction with an anti-tumor preparation. In addition, related compositions comprising an ARB or a compound of Formula (I) and an antigen, vaccine, or anti-tumor preparation are provided.

The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases of fibrosis prominent such as COPD, liver fibrosis and atherosclerosis. The novel pharmaceutical comprises targeting moieties bonded to the receptor which receives up regulation and / or excess expression in or not in siclen region. The imaging moieties contained in the targeting moieties carries imaging moieties which can form image for diagnosis, optional linkers and peptides. The novel pharmaceutical compound has high affinity to angiotensin receptor, in particular to angiotensin II(AngII)I type(AT1)receptor.

A method of determining whether an individual has schizophrenia or the propensity to develop schizophrenia is provided. The method involves the detection of autoantibodies to the angiotensin AT1 receptor. Diagnostic kits and assays arc also provided within the scope of the invention.

The present invention relates to methods and pharmaceutical compositions for renal protection in a mammal in need thereof, such as a mammal having a disease manifested by atrial enlargement and / or remodeling or suffering from hypertension or heart failure or being prone to suffering from hypertension and / or heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said mammal.

The present invention relates to a novel pyrimidinone compounds and the pharmaceutical acceptable salts thereof having remarkable antagonistic action against angiotensin II receptor, thereby, being useful in treating cardiovascular disease caused by binding angiotensin II to its receptor.

The present application is directed to the identification of mutations and / or polymorphisms in the Dual Endothelin-1 / Angiotensin II Receptor (Dear) that indicate susceptibility to, or show current affliction with, hypertension. Additionally, the present invention discloses methods for the modulation of angiogenesis via the regulation of Dear.

The invention relates to [[(2-n-propyl-4-methyl-1H-benzimidazole)-6-yl] formamide-1-yl] methyl biphenylacylamine tetrazole compounds, a synthetic method and application, and belongs to the technical field of medicaments. The structural formula of the compound is shown in the specification, wherein R1 is the [[(2-n-propyl-4-methyl-1H-benzimidazole)-6-yl] formamide-1-yl] methyl biphenylacylamine tetrazole compounds, and M is hydrogen, potassium or sodium. Experiments prove that the compounds have the excellent dual antagonist activity of an angiotensin II receptor and an endothelin receptor, and can be used for preparing medicaments for treating cardiovascular and cerebrovascular diseases.

The present invention relates to stable solid pharmaceutical compositions comprising valsartan as the active pharmaceutical ingredient. Optionally the compositions comprise one or more further active pharmaceutical ingredients. The invention further relates to methods for preparing said compositions and to the use of said compositions in the treatment or prevention of angiotensin receptor mediated disorders, in particular hypertension and related disorders.

Disclosed is a method of inhibiting production of IFN-Γ in patients having a transplanted organ. The method involves administering to the patient an amount of an angiotensin receptor-blocking compound, the amount being effective to inhibit production of IFN-Γ by T cells. The method can be used to treat inflammation involving an allograft, to treat chronic allograft nephropathy, and to treat other pathologies associated with allograft rejection.

The present invention provides compounds of Formula (I):wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Provided herein are pharmaceutical compositions for the treatment of wounds, including chronic wounds and diabetic ulcers. The pharmaceutical compositions, which comprise valsartan, inhibit angiotensin receptors in the wound bed. Also provided herein are methods of making the pharmaceutical compositions of the invention, and methods for treating wounds in patients in need thereof.